华兰生物(002007.SZ)：帕博利珠单抗注射液获准开展临床试验

Core Viewpoint - Hualan Biological (002007.SZ) announced that its associate company, Hualan Ankang Biological Co., Ltd., received the Clinical Trial Approval Notification from the National Medical Products Administration for the clinical trial of Pembrolizumab injection as a biosimilar [1] Group 1: Company Information - Hualan Ankang Biological Co., Ltd. is advancing the clinical trial of Pembrolizumab, a humanized monoclonal antibody targeting the programmed cell death protein 1 (PD-1) [1] - The drug Pembrolizumab is designed to block the interaction between PD-1 and its ligands PD-L1/PD-L2, thereby restoring the tumor-killing function of T cells and enhancing the immune system's ability to combat tumors [1] Group 2: Industry Context - Pembrolizumab, as an immune checkpoint inhibitor, has become a standard treatment option for various advanced malignancies, revolutionizing the landscape of cancer treatment [1]